Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.64 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.64 |
| ▸ | CYP4Z1 | Q86W10 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | CYP4F11 | Q9HBI6 | 1/20 | 0.43 |
| ▸ | CYP4F12 | Q9HCS2 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12329325 | 0.91 | CYP4Z1 (0.53) | CYP4F2CYP4A11CYP4Z1TDP1CYP4F11 | |
| SCHEMBL765422 | 0.88 | CYP4Z1 (0.53) | CYP4F2CYP4A11CYP4Z1TDP1CYP4F11 | |
| SCHEMBL764926 | 0.87 | CYP4F2 (0.68) | CYP4F2CYP4A11CYP4Z1TDP1HRH3 | |
| SCHEMBL68902 | 0.85 | CYP4F2 (0.85) | CYP4F2CYP4A11CYP4Z1TDP1HRH3 | |
| SCHEMBL25146565 | 0.83 | CYP4F2 (0.62) | CYP4F2CYP4A11CYP4Z1TDP1HRH3 | |
| Hydrochloric Acid SCHEMBL11472812 | 0.83 | CYP4F2 (0.62) | CYP4F2CYP4A11CYP4Z1TDP1HRH3 | |
| SCHEMBL1587300 | 0.82 | CYP4F2 (0.74) | CYP4F2CYP4A11CYP4Z1TDP1HRH3 | |
| SCHEMBL13103434 | 0.82 | FFAR1 (0.55) | LMNAL3MBTL1 | |
| SCHEMBL879019 | 0.81 | CYP4F2 (0.68) | CYP4F2CYP4A11CYP4Z1TDP1HRH3 | |
| SCHEMBL19024845 | 0.80 | CYP4F2 (0.54) | CYP4F2CYP4A11CYP4Z1TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304403-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-06 | — | — | US | disclosed |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-7652023-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-26 | — | — | US | disclosed |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2007062308-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | CYP4F2 1512/4885CYP4A11 357/4885CYP4Z1 1859/4885 |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | CYP4F2 1512/4885CYP4A11 357/4885CYP4Z1 1859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.